[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mrna-vaccine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mrna-vaccine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,72,95,122,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644880","phase-1-a-single-arm-open-label-prospective-study-evaluating-the-safety-tolerability-and-immunogenicity-of-the-neooviv-vaccine-in-patients-with-ovarian-cancer-after-surgery-100644880",false,"NCT07676890","A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery","NeoOVIV","Inclusion Criteria:\n\n1. Female, aged between 18 and 75 years (inclusive) at the time of signing the written informed consent form (ICF)\n2. Patients with histopathologically confirmed epithelial ovarian cancer (EOC), including: a) Patients with Stage II (Stage IIA\u002FIIB, tumor confined to the pelvis with no extra-abdominal metastasis) or Stage III (Stage IIIA\u002FIIIB\u002FIIIC, tumor involving the serosal surface of intra-abdominal viscera or regional lymph node metastasis) disease, in accordance with the International Federation of Gynecology and Obstetrics (FIGO) 2014 Staging System; b) Have undergone cytoreductive surgery (CRS), with postoperative pathological confirmation of R1 resection (R1 defined as microscopic residual tumor at the surgical margin ≤ 1 mm); c) Qualified tumor tissue obtained during surgery is available for neoantigen screening: ① Fresh tumor tissue ≥ 100 mg (collected on the day of surgery and immediately immersed in RNA stabilization reagent); or ② ≥ 5 unstained sections of formalin-fixed paraffin-embedded (FFPE) tissue (each with a thickness of 5 μm, tumor cellularity ≥ 30%, and no significant necrosis); d) Whole-exome sequencing (WES) combined with RNA sequencing confirms the presence of ≥ 5 \"usable neoantigens\" (defined as: HLA binding affinity IC50 \\\u003C 500 nM, and transcript expression level of the mutant gene in transcripts per million (TPM) ≥ 1);\n3. In accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, postoperative contrast-enhanced pelvic MRI\u002FCT shows no macroscopic residual disease (R2 resection), and lung metastasis, liver metastasis, and bone metastasis are excluded;\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 1 (0: Fully ambulatory, no restriction in daily activities; 1: Ambulatory and able to perform light physical activity, no significant fatigue or dyspnea), with an expected overall survival of ≥ 1 year;\n5. Adequate function of major organs, with relevant laboratory test results within 14 days prior to enrollment meeting the following requirements (no blood transfusion or blood product administration, no use of hematopoietic growth factors, albumin, or other blood products during this period): Hematology tests: Hemoglobin (Hb) ≥ 90 g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count (PLT) ≥ 100 × 10⁹\u002FL; Serum biochemistry tests: Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine (SCr) ≤ 1.5 × ULN, or creatinine clearance rate (CrCl) ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula; Endocrine tests: Thyroid-stimulating hormone (TSH), free triiodothyronine (free T3), and free thyroxine (free T4) are within the normal reference range; Coagulation function tests: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.2 × ULN;\n6. Women of childbearing potential (WOCBP) must have a negative serum β-human chorionic gonadotropin (β-HCG) test prior to enrollment, and agree to use effective contraceptive measures (e.g., condoms, intrauterine device \\[IUD\\]) during the study period (from the first dose administration to 6 months after the last dose administration);\n7. Good treatment compliance, and the patient and their family members agree to cooperate with and complete the scheduled survival follow-up.\n\nExclusion Criteria:\n\n1. Histopathologically confirmed non-epithelial ovarian cancer, including ovarian germ cell tumors (e.g., teratoma, yolk sac tumor), sex cord-stromal tumors (e.g., granulosa cell tumor), and metastatic ovarian tumors (e.g., Krukenberg tumor metastatic to the ovary from the gastrointestinal tract);\n2. R2 resection (macroscopic residual disease) after cytoreductive surgery, or postoperative imaging (contrast-enhanced pelvic MRI\u002FCT, chest CT) showing distant metastasis (e.g., lung, liver, brain metastasis), or FIGO stage IV disease;\n3. Prior treatment with any therapeutic cancer vaccine (e.g., peptide vaccine, DNA vaccine, other mRNA vaccines); or prior use of immune checkpoint inhibitors (e.g., anti-PD-1\u002FPD-L1 antibodies, anti-CTLA-4 antibodies) with the last dose administered ≤ 30 days before enrollment;\n4. Severe surgery-related complications within 4 weeks postoperatively, including but not limited to: intra-abdominal infection requiring intravenous antibiotics for ≥ 7 days, enteric fistula requiring surgical repair, massive hemorrhage requiring transfusion ≥ 400 mL within 24 hours, severe adhesive intestinal obstruction requiring gastrointestinal decompression for ≥ 3 days;\n5. Active autoimmune disease, or a history of autoimmune disease currently requiring long-term (≥ 2 weeks) immunosuppressive therapy, including but not limited to: rheumatoid arthritis requiring prednisone ≥ 10 mg\u002Fday or equivalent immunosuppressants, systemic lupus erythematosus requiring hydroxychloroquine plus glucocorticoids, ulcerative colitis with acute flare within the past 1 year, multiple sclerosis with relapse within the past 2 years, autoimmune thyroiditis requiring high-dose levothyroxine \\> 150 μg\u002Fday;\n6. Active infection within 1 month before enrollment, including but not limited to: Bacterial infections: pneumonia requiring intravenous antibiotics, pyelonephritis with positive urine culture and fever; Viral infections: HBsAg-positive with HBV DNA ≥ 1×10³ IU\u002FmL (untreated); HCV RNA-positive (untreated with direct-acting antivirals or persistently positive after treatment); HIV-positive; acute varicella-zoster virus (VZV) or cytomegalovirus (CMV) infection with fever or organ involvement; Fungal infections: pulmonary candidiasis, aspergillosis (confirmed by imaging and positive fungal culture);\n7. Severe organ dysfunction or history thereof: acute myocardial infarction, unstable angina, heart failure (NYHA class ≥ II), severe arrhythmia (e.g., ventricular tachycardia requiring medication) within the past 6 months; uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite antihypertensive treatment); acute exacerbation of chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (CT-proven with FEV1\u002FFVC \\\u003C 70% on pulmonary function testing), active pulmonary tuberculosis (positive sputum smear or strongly positive tuberculin test without completed standard anti-tuberculosis therapy); liver cirrhosis (Child-Pugh class B or higher), active hepatitis (ALT\u002FAST \\> 5×ULN), gastrointestinal bleeding within the past 1 year (e.g., esophagogastric variceal bleeding); chronic renal failure requiring dialysis or creatinine clearance \\\u003C 50 mL\u002Fmin (calculated by Cockcroft-Gault formula), nephrotic syndrome (24-hour urinary protein \\> 3.5 g);\n8. Uncontrolled diabetes mellitus (fasting blood glucose ≥ 11.1 mmol\u002FL despite hypoglycemic agents); hyperthyroidism or hypothyroidism with free T3 and free T4 remaining outside the normal range despite medical treatment;\n9. Hypersensitivity to any component of the investigational products, including but not limited to: mRNA vaccine components (liposomes, poly-ICLC adjuvant), anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab); or prior severe allergic reactions to similar biological agents (e.g., COVID-19 mRNA vaccines, other monoclonal antibodies) such as anaphylactic shock, laryngeal edema, bronchospasm;\n10. Use of immunosuppressive agents within 2 weeks before enrollment, including but not limited to: glucocorticoids (prednisone ≥ 10 mg\u002Fday or equivalent), cyclosporine, tacrolimus, methotrexate, azathioprine; or planned use of such agents during the trial;\n11. Diagnosis of another malignancy other than ovarian cancer within the past 5 years, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and ductal carcinoma in situ of the breast, all of which must have undergone radical surgery with no recurrence;\n12. Pregnant (positive serum β-HCG before enrollment) or lactating female; woman of childbearing potential refusing effective contraception during the trial (from first dose to 6 months after last dose);\n13. Psychiatric disorders (e.g., dementia, major depressive disorder, schizophrenia) or cognitive impairment that prevents understanding of trial procedures or compliance with follow-up;\n14. Participation in another interventional clinical trial (receipt of investigational drugs, devices, or other study interventions) within 30 days before enrollment; or currently in the follow-up period of another clinical trial without completing the final assessment;\n15. Unable to provide written informed consent or unwilling to comply with trial-related requirements for personal reasons;\n16. Any other condition deemed inappropriate by the investigator.","FEMALE","18 Years","75 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase I, single-arm, open-label, dose-escalation study in patients with stage II or III ovarian cancer after surgery. The study will evaluate the safety, tolerability, immune response, and preliminary clinical activity of NeoOVIV, a personalized mRNA-lipid nanoparticle vaccine, when given with standard adjuvant chemotherapy and a PD-1 antibody.",[27,28],"Ovarian Cancer","mRNA Vaccine",[27,30],"mRNA vaccine","NOT_YET_RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":21},"2026-07-31",{"date":39,"type":21},"2028-05-30",{"name":41,"class":42},"West China Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100639231","phase-1-safety-tolerability-and-preliminary-antitumor-activity-of-cationic-peptide-il22bp-mrna-in-advanced-solid-tumors-100639231","NCT07583654","Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors","A Clinical Trial of Cationic Peptide-IL22BP mRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years and ≤70 years.\n* Histopathologically confirmed advanced recurrent\u002Fmetastatic malignant solid tumors that are refractory to second-line treatment and have no available standard clinical therapeutic options (e.g., advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* Expected overall survival ≥3 months.\n* Interval from the last chemotherapy, radiotherapy, or surgery ≥28 days.\n* Interval from the last use of nitrosourea or mitomycin C ≥6 weeks.\n* Adequate organ function, defined by the following laboratory parameters within 14 days prior to enrollment:\n* Hemoglobin ≥90 g\u002FL (no blood transfusion within 14 days).\n* Absolute neutrophil count \\>1.5 × 10⁹\u002FL.\n* Platelet count ≥80 × 10⁹\u002FL.\n* Total bilirubin ≤1.5 × upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × -ULN in case of liver metastasis).\n* Creatinine clearance ≥60 mL\u002Fmin (calculated by Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) ≥50%.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Participation in another investigational drug clinical trial within 4 weeks.\n* Tumor located adjacent to major blood vessels or trachea.\n* Uncontrolled cardiac clinical symptoms or diseases, including New York Heart Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular\u002Fventricular arrhythmias requiring treatment or intervention.\n* Female patients who are pregnant or lactating.\n* Active pulmonary tuberculosis, bacterial or fungal infection (≥Grade 2 per NCI-CTCAE version 5.0), active human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection.\n* History of uncontrollable psychoactive substance abuse or presence of mental disorders.\n* Any active autoimmune disease or history of autoimmune disease, including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism.\n* Subjects with vitiligo or childhood asthma in complete remission (no adult intervention required) are eligible; subjects with asthma requiring bronchodilator therapy are excluded.\n* Receiving immunosuppressive therapy.\n* History of drug abuse or known medical, psychological, or social conditions that interfere with study compliance (e.g., alcoholism or illicit drug addiction).\n* Known hypersensitivity, allergy, or intolerance to the study drug CPIL22BP mRNA (including any excipients), or history of severe allergic reactions to any drugs, foods, or vaccines (e.g., anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local Arthus reaction, etc.).\n* Female subjects planning pregnancy, or male subjects whose partner plans pregnancy, from screening until 12 months after the last study drug injection.\n* Any concomitant disease that, in the investigator's judgment, may seriously compromise patient safety or prevent the subject from completing the study.","ALL","70 Years",{"count":53,"type":21},18,[24],"The goal of this phase 1 clinical trial is to evaluate the safety, tolerability, and preliminary antitumor activity of a peptide-delivered IL-22BP biotherapy in patients with advanced solid tumors. The main questions it aims to answer are:\n\nIs the IL-22BP formulation safe and tolerable? Does the IL-22BP formulation show preliminary antitumor activity?",[28,57,58,59],"Solid Tumor Cancer","Peptides","Cancer Metastatic",[30,61,62,63],"Cancer metastasis","Solid tumor","IL-22","2026-05-06",{"date":66,"type":35},"2026-05-13",{"date":68,"type":21},"2026-05-30",{"date":70,"type":21},"2027-12-30",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100596091","phase-1-clinical-trial-of-il---22bp-safety-tolerability-and-antitumor-activity-in-refractory-solid-tumors-100596091","NCT07040943","Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.","A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.","Inclusion Criteria:\n\n1. Male or female patients: aged ≥ 18 years old and ≤ 70 years old;\n2. Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent\u002Fmetastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.);\n3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1;\n4. Expected survival time ≥ 3 months;\n5. More than 28 days since the last chemotherapy\u002Fradiotherapy\u002Fsurgery;\n6. More than 6 weeks since the last use of nitrosoureas or mitomycin C;\n7. Main organ functions are in good condition;\n8. Sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Have participated in other drug clinical trials within 4 weeks;\n2. The tumor is located close to major blood vessels or the trachea;\n3. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of NYHA class II or above, unstable angina pectoris, having had a myocardial infarction within 1 year, and having clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.\n4. For female subjects: pregnant or lactating women.\n5. Patients have active tuberculosis, bacterial or fungal infections (≥ grade 2 of NCI-CTCAE 5.0); have active HIV infection, active HBV infection, or HCV infection.\n6. Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders;\n7. Subjects have any active autoimmune diseases or a history of autoimmune diseases (such as, but not limited to: uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or those whose asthma in childhood has been completely relieved and who do not require any intervention in adulthood can be included; subjects with asthma that requires bronchodilators for medical intervention cannot be included).\n8. Subjects are currently receiving immunosuppressive treatment.\n9. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcoholism or drug use.\n10. Known to be allergic, hypersensitive, or intolerant to the studied IL-22BP (including any excipients). Have a severe allergy history to any drugs, foods, or vaccines in the past, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrotizing reaction (Arthus reaction), etc.\n11. From the screening period to 12 months after the completion of drug injection, female subjects have pregnancy plans or the partners of male subjects have pregnancy plans.\n12. According to the investigator's judgment, there are concomitant diseases that seriously endanger patient safety or affect the patient's completion of the study.",{"count":5,"type":21},[24],"This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.",[83,28,84],"Refractory Malignant Solid Tumors","Interleukin","RECRUITING","2026-04-07",{"date":88,"type":35},"2026-04-13",{"date":90,"type":35},"2025-06-29",{"date":92,"type":21},"2026-07-01",{"name":41,"class":42},2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100625099","phase-1-study-to-evaluate-the-safety-of-a-lyophilized-rsv-mrna-vaccine-100625099","NCT07418229","Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety of Different Doses of a Lyophilized RSV mRNA Vaccine in Adults Aged 18 Years and Older","Inclusion Criteria:\n\n1. Participants can understand and voluntarily sign the informed consent form;\n2. Able to provide legal identity documents;\n3. Healthy individuals aged 18 years and above;\n4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures (such as correct use of condoms, or female participants using combined oral contraceptives, intrauterine devices) from the time the participant signs the informed consent form until 6 months after the administration of the investigational vaccine, and have no plans to donate sperm or ovums; Female participants of childbearing potential must also have adopted effective contraceptive measures within 2 weeks before enrollment.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from this trial:\n\n1. Those with fever on the day of vaccination with the trial vaccine, with an axillary temperature \\> 37.0℃ before vaccination;\n2. Those with a history of previous RSV vaccination, or a history of RSV infection within 6 months before enrollment.\n3. Known to be allergic to vaccines or vaccine components;\n4. Before vaccination, the electrocardiogram examination and clinical laboratory test indicators specified in the protocol are abnormal and clinically significant;\n5. Female participants who are breastfeeding or pregnant;\n6. Having autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, splenectomy, HIV infection);\n7. History of poorly controlled chronic diseases or severe diseases, including but not limited to cardiovascular diseases (such as hypertension uncontrolled by drugs, i.e., systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg for participants aged 18-59 years old, systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg for participants aged 60 years old and above, as well as congenital heart disease, atrial fibrillation, myocarditis, pericarditis), hematological system diseases, liver and kidney diseases, respiratory system diseases, malignant tumors, history of transplantation of major functional organs, or any other diseases or physiological conditions that the researcher believes can interfere with the trial results;\n8. Current encephalopathy (such as damage to cerebral nerve tissue caused by congenital hypoplasia of the brain, brain trauma, brain tumors, cerebral hemorrhage, brain infection, chemical drug poisoning, etc.);\n9. Severe neurological diseases, such as a history of demyelinating diseases including but not limited to Guillain-Barré syndrome, multiple sclerosis, neuromyelitis optica, acute disseminated encephalomyelitis, etc., or a history of convulsions, epilepsy, or a family history of mental illness;\n10. Having a doctor-diagnosed coagulation dysfunction (such as coagulation factor deficiency, coagulative diseases, abnormal platelets);\n11. Having received systemic immunosuppressive agents or other immunomodulatory treatments (prednisone \\[≥ 20 mg\u002Fday\\] or its equivalent) for ≥ 14 days within the past 3 months, cytotoxic therapy, or planning to receive such treatments during the study period;\n12. Having received immunoglobulin or other blood products within 3 months before receiving the trial vaccine, or planning to receive such treatments during the study period;\n13. Currently participating in other clinical trials, or planning to receive such drugs or vaccines during the study period;\n14. Having received live attenuated vaccines within the past 14 days or other vaccines with processes such as subunit or inactivated vaccines within 7 days;\n15. Having various acute diseases or acute exacerbation of chronic diseases within the past 7 days, or known or suspected active infection;\n16. Axillary temperature \\> 37.0℃ within the past 3 days, or use of anti-allergic drugs, non-steroidal antipyretic analgesics, etc.;\n17. Those with skin damage, inflammation, ulceration, rash, scarring, or other conditions at the target vaccination site that may interfere with vaccination or observation of local reactions;\n18. According to the researcher's judgment, participants have any other factors that make them unsuitable for participating in the clinical trial.",true,{"count":104,"type":21},60,[24],"To evaluate the safety of Sinovac RSV mRNA among participants aged ≥18 years",[108,28],"RSV",[110],"RSV vaccine","2026-02-11",{"date":113,"type":35},"2026-02-18",{"date":115,"type":21},"2026-03-09",{"date":117,"type":21},"2027-05-30",{"name":119,"class":120},"Sinovac Biotech Co., Ltd","INDUSTRY",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":102,"sex":50,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":121},"100623697","phase-1-study-to-evaluate-the-safety-and-immunogenicity-of-a-lyophilized-herpes-zoster-virus-mrna-vaccine-100623697","NCT07400003","Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","A Randomized, Double-Blind, Controlled Phase I\u002FII Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of a Lyophilized Herpes Zoster Virus mRNA Vaccine in Adults Aged 40 Years and Older","Inclusion Criteria:\n\n* Phase I: Age ≥ 40 years; Phase II: Age ≥ 50 years;\n* Participants are able to understand and voluntarily sign the informed consent form;\n* Able to provide legal identification;\n* Participants of childbearing potential and their sexual partners agree to voluntarily adopt effective contraceptive measures from the signing of the informed consent form until 6 months after the last dose of the investigational vaccine, with no plans for sperm or egg donation;\n* Agree to comply with the visit schedule, sample collection, vaccination, and other trial procedures throughout the study period, and remain accessible at all times during the trial.\n\nExclusion Criteria:\n\n* History of chickenpox or herpes zoster in adulthood;\n* History of chickenpox or herpes zoster vaccination (including administration of registered products or participation in clinical trials of chickenpox or herpes zoster vaccines);\n* Close contact with patients infected with chickenpox or herpes zoster within the past 30 days;\n* Clinically significant abnormalities in protocol-specified clinical laboratory tests prior to vaccination (applicable to Phase I clinical trials only):\n\nA. Hematological parameters: White blood cell count (WBC), hemoglobin (Hb), platelet count (Plt); B. Blood biochemical parameters: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), fasting blood glucose (Glu), creatinine (CR); C. Urinalysis parameter: Urine protein (PRO); D. Coagulation parameters: Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), international normalized ratio (INR); E. 12-lead electrocardiogram (ECG).\n\n* Poorly controlled chronic diseases or significant medical history, including but not limited to cardiovascular diseases (e.g., poorly controlled hypertension defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg for participants aged 40-59 years prior to enrollment, or systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg for participants aged ≥60 years), metabolic disorders (e.g., poorly controlled diabetes), hematological diseases, hepatic or renal diseases, digestive system diseases, respiratory system diseases, history of major organ transplantation, or malignancy within the past five years;\n* History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that increases the risk of myocarditis or pericarditis;\n* Autoimmune diseases, immunodeficiency diseases, or family history thereof (including but not limited to psoriasis, systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, acute disseminated encephalomyelitis, facial paralysis, hypersensitivity reactions, polymyalgia rheumatica, rheumatoid arthritis, Guillain-Barré syndrome, asplenia, functional asplenia, HIV infection);\n* Coagulation disorders (e.g., coagulation factor deficiencies, platelet abnormalities, or other coagulopathies);\n* Current or previous severe neurological disorders (epilepsy, convulsions, or seizures) or psychiatric illnesses, or family history of psychiatric disorders;\n* Acute illnesses or acute exacerbations of chronic diseases within the past 7 days, or known or suspected active infections;\n* Immunosuppressive therapy or other immunomodulatory treatments (prednisone ≥20 mg\u002Fday or equivalent for \\>14 days), cytotoxic therapy within the past 6 months, or planned use during the trial;\n* Administration of immunoglobulins or other blood products within the past 3 months (use of hepatitis B immunoglobulin within the past 1 month), or planned use during the trial;\n* Participation in other clinical studies within the past 30 days or planned participation during this trial;\n* Vaccination with live-attenuated vaccines or nucleic acid vaccines within the past 28 days, or vaccination with subunit, inactivated, or other types of vaccines within the past 14 days;\n* Known allergy to vaccines or vaccine components, such as urticaria, dyspnea, or angioedema following vaccination;\n* Pregnancy, lactation, or positive urine pregnancy test in female participants;\n* Fever (axillary temperature ≥37.3°C) within 3 days prior to vaccination or use of antipyretics, analgesics, or antihistamines (e.g., acetaminophen, ibuprofen, loratadine, cetirizine, etc.) as reported during inquiry;\n* Physical examination deemed unsatisfactory on the day of planned vaccination;\n* Skin lesions, inflammation, ulcers, rashes, scars, or other conditions at the target injection site that may interfere with administration or local reaction assessment;\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial.","40 Years",{"count":131,"type":21},519,[24,133],"PHASE2","This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.",[136,28],"Herpes Zoster","2026-02-02",{"date":139,"type":35},"2026-02-10",{"date":141,"type":35},"2026-01-06",{"date":143,"type":21},"2027-04-30",{"name":119,"class":120},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":121},"100600647","phase-1-a-clinical-trial-evaluating-il-22bplnp-compound-in-refractory-malignant-solid-tumors-for-safety-tolerability-and-activity-100600647","NCT07100210","A Clinical Trial Evaluating IL-22BP\u002FLNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity","A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of IL-22BP\u002FLNP Compound in Refractory Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients: aged ≥ 18 years old and ≤ 70 years old;\n2. Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent\u002Fmetastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.);\n3. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1;\n4. Expected survival time ≥ 3 months;\n5. More than 28 days since the last chemotherapy\u002Fradiotherapy\u002Fsurgery;\n6. More than 6 weeks since the last use of nitrosoureas or mitomycin C;\n7. Main organ functions are in good condition;\n8. Sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Have participated in other drug clinical trials within 4 weeks;\n2. The tumor is located close to major blood vessels or the trachea;\n3. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of NYHA class II or above, unstable angina pectoris, having had a myocardial infarction within 1 year, and having clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.\n4. For female subjects: pregnant or lactating women.\n5. Patients have active tuberculosis, bacterial or fungal infections (≥ grade 2 of NCI-CTCAE 5.0); have active HIV infection, active HBV infection, or HCV infection.\n6. Those with a history of psychotropic drug abuse who are unable to quit or have mental disorders;\n7. Subjects have any active autoimmune diseases or a history of autoimmune diseases (such as, but not limited to: uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or those whose asthma in childhood has been completely relieved and who do not require any intervention in adulthood can be included; subjects with asthma that requires bronchodilators for medical intervention cannot be included).\n8. Subjects are currently receiving immunosuppressive treatment.\n9. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcoholism or drug use.\n10. Known to be allergic, hypersensitive, or intolerant to the studied IL-22BP\u002FLNP (including any excipients). Have a severe allergy history to any drugs, foods, or vaccines in the past, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrotizing reaction (Arthus reaction), etc.\n11. From the screening period to 12 months after the completion of drug injection, female subjects have pregnancy plans or the partners of male subjects have pregnancy plans.\n12. According to the investigator's judgment, there are concomitant diseases that seriously endanger patient safety or affect the patient's completion of the study.",{"count":5,"type":21},[24],"This study aims to investigate the safety and efficacy of the IL-22BP\u002FLNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.",[83,28,84],"2025-12-21",{"date":158,"type":35},"2025-12-29",{"date":160,"type":35},"2025-01-20",{"date":162,"type":21},"2026-02-20",{"name":164,"class":42},"Xingchen Peng"]